Cantargia AB (FRA:7V3) Other Current Liabilities : €3.74 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cantargia AB Other Current Liabilities?

Cantargia AB's other current liabilities for the quarter that ended in Dec. 2024 was €3.74 Mil.

Cantargia AB's quarterly other current liabilities increased from Jun. 2024 (€1.73 Mil) to Sep. 2024 (€2.13 Mil) and increased from Sep. 2024 (€2.13 Mil) to Dec. 2024 (€3.74 Mil).

Cantargia AB's annual other current liabilities declined from Dec. 2022 (€4.26 Mil) to Dec. 2023 (€2.83 Mil) but then increased from Dec. 2023 (€2.83 Mil) to Dec. 2024 (€3.74 Mil).

Cantargia AB Other Current Liabilities Historical Data

The historical data trend for Cantargia AB's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB Other Current Liabilities Chart

Cantargia AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Current Liabilities

Get a 7-Day Free Trial

1.91

3.07

4.26

2.83

3.74

Cantargia AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Current Liabilities	Get a 7-Day Free Trial															2.83	1.63	1.73	2.13	3.74

Cantargia AB Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Cantargia AB Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Cantargia AB's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cantargia AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

CANTA:Sweden

Address

Scheelevagen 27, Lund, SWE, SE-223 63

Website

https://www.cantargia.com

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB Headlines

No Headlines